|
Kidney Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
CCL2/CCR2 signaling is believed to play an important role in kidney diseases.
|
31498850 |
2019 |
|
Kidney Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
NGAL levels were measured via enzyme-linked immunosorbent assays, as were those of three additional urinary biomarkers for kidney diseases: Monocyte chemotactic protein-1 (MCP-1), liver-type fatty acid-binding protein (L-FABP), and human epididymis secretory protein 4 (HE4).
|
31242630 |
2019 |
|
Kidney Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
ALPK1 regulates streptozotocin-induced nephropathy through CCL2 and CCL5 expressions.
|
31557402 |
2019 |
|
Kidney Diseases
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Folic acid induced nephropathy was associated with the overexpression of inflammatory markers MCP-1, F4/80, type IV collagen, fibronectin and TGF-β1 compared to control groups, which were partially attenuated by metformin treatment.
|
29380373 |
2018 |
|
Kidney Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
Chemokine monocyte chemoattractant protein-1 (MCP-1) has been proved as a potential urinary biomarker in nephropathies.
|
28919104 |
2018 |
|
Kidney Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
Conclusion In our cohort of SLE patients, we found that urinary NGAL and MCP-1 in addition to anti-C1q antibodies were useful biomarkers for the identification of renal involvement and discrimination of active lupus nephritis among patients with renal disease.
|
29073812 |
2018 |
|
Kidney Diseases
|
0.300 |
AlteredExpression
|
group |
BEFREE |
While no difference in proportion of samples with detectable uAPRIL was observed between SLE, HCs and IgAN patients, both uAPRIL and uMCP-1 were significantly detectable in higher proportions of patients with active renal disease.
|
30301439 |
2018 |
|
Kidney Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
Monocyte chemoattractant protein-1 (MCP-1) has been shown to attract macrophages in kidney diseases.
|
28434946 |
2017 |
|
Kidney Diseases
|
0.300 |
GeneticVariation
|
group |
BEFREE |
These findings suggest that -2518G allele of MCP-1 -2518 A/G polymorphism is associated with renal disorders and may influence MCP-1 gene expression among Indian SLE patients.
|
28433894 |
2017 |
|
Kidney Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
Our results suggest that the AA genotype might be a risk factor for the progression of renal disease in FSGS and MCP1 genotyping may help the physicians to predict prognosis in these patients.
|
26335292 |
2015 |
|
Kidney Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
Monocyte chemoattractant protein-1 (MCP-1) plays a major role in the pathogenesis and progression of different types of human renal disease.
|
25655256 |
2015 |
|
Kidney Diseases
|
0.300 |
GeneticVariation
|
group |
BEFREE |
MCP-1 and its A/G gene polymorphism have been implicated in the pathogenesis of some renal diseases.
|
26429331 |
2015 |
|
Kidney Diseases
|
0.300 |
GeneticVariation
|
group |
BEFREE |
MCP-1 -2518G/A gene polymorphism was not associated with nephropathy risk in T2DM among Chinese, Koreans, and Turks.
|
24059294 |
2014 |
|
Kidney Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
Monocyte chemoattractant protein 1 (MCP‑1) is involved in the pathogenesis of renal diseases, diabetes, and hepatitis B virus (HBV) clearance.
|
24382482 |
2014 |
|
Kidney Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
CCL2 has already been shown to be involved in the development of TIF but CCL7, a close relative of CCL2 and able to bind to similar receptors, has not been studied in renal disease.
|
23872063 |
2013 |
|
Kidney Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
In conclusion, these data suggest that MCP-1 has potential as a biomarker of AKI and provide "proof of concept" that urinary histone assessments provide mechanistic insight among patients with kidney disease.
|
21071523 |
2011 |
|
Kidney Diseases
|
0.300 |
GeneticVariation
|
group |
BEFREE |
The MCP-1 genotypes were determined in 43 patients with nephropathy and 43 without nephropathy and a control group of 105 healthy individuals.
|
20960176 |
2010 |
|
Kidney Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
CCL2 DNA vaccine to treat renal disease.
|
18768165 |
2009 |
|
Kidney Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
The co-occurrence of risk associated genotypes (II, -2518GG (CCL2), DD (CCR5) and 279Gln/Gln (MMP9) conferred a tenfold increased risk of nephropathy among type 2 diabetics (p<0.0002).
|
19357773 |
2009 |
|
Kidney Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
Monocyte chemoattractant protein-1 (MCP-1) is a potent chemokine that is involved in the inflammatory response in renal disease.
|
17977907 |
2008 |
|
Kidney Diseases
|
0.300 |
AlteredExpression
|
group |
BEFREE |
MCP-1 expression in renal tubuli is enhanced in proteinuric states, irrespective of the types of renal disease, and this increased MCP-1 expression probably contributes to renal tubular damage in proteinuric states.
|
17261994 |
2007 |
|
Kidney Diseases
|
0.300 |
GeneticVariation
|
group |
BEFREE |
The AA genotype at MCP-1 -2518 was an independent risk factor for the progression of renal disease in Japanese patients with IgAN, and was closely associated with renal survival.
|
16362156 |
2005 |
|
Kidney Diseases
|
0.300 |
Biomarker
|
group |
RGD |
In this study, we tested the effect of DNA vaccination encoding the C-C chemokines MCP-1 and RANTES in a rat model of adriamycin nephropathy.
|
15882261 |
2005 |
|
Kidney Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
Thus, this study tested whether pro-oxidant iron/carbohydrate complexes, used to treat iron deficiency, induce MCP-1 in renal/extrarenal tissues, in plasma, and in the setting of experimental nephropathy.
|
16164630 |
2005 |
|
Kidney Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
MCP-1 and EGF seem to be involved in the pathogenesis of tubulointerstitial damage in congenital obstructive nephropathy, and their urine excretion may represent a powerful prognostic marker in this form of renal disease.
|
10886563 |
2000 |